Skip to main content
Clinical Trials/NL-OMON34613
NL-OMON34613
Completed
Not Applicable

A Phase I, Dose Escalation Study on the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) and its Comparability to NovoSeven® in Healthy Male Volunteers Pre-Treated with Fondaparinux - Recombinant human factor VIIa FIH

Centre for Human Drug Research0 sites36 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
haemophilia
Sponsor
Centre for Human Drug Research
Enrollment
36
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Healthy male volunteers, 19\-45 years of age, BMI 19\-30 kg/m^2

Exclusion Criteria

  • Bleeding or coagulation disorder, recent trauma, thromboembolic event, history of administration of any rhFVIIa product, positive reaction to rabbit allergens. See protocol for detailed list of exclusion criteria.

Outcomes

Primary Outcomes

Not specified

Similar Trials